Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04844970 · ClinicalTrials.gov registry record · Phase 2
Anamorelin Study for Advanced Pancreatic Cancer
A Phase 2 study, sponsored by Lahey Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT04844970: Clinical Trial Phase 2 study, sponsored by Lahey Clinic.
NCT04844970 is a Phase 2 study that was terminated before completion, run by Lahey Clinic. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04844970, a Phase 2 study, was terminated before completion, sponsored by Lahey Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects will be instructed to take the study drug at least 1 hour before their first meal of the day
Primary Outcome
Does anamorelin HCl dosed at 100mg per day vs. placebo demonstrate superiority on body weight gain and improvement in anorexia symptoms in patients undergoing first-line chemotherapy for incurable pancreatic cancer.
Interventions
- DRUG Placebo
- DRUG Anamorelin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 2 |
Why NCT04844970 stopped before completion
NCT04844970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04844970 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04844970 about?
NCT04844970 is a clinical study titled "Anamorelin Study for Advanced Pancreatic Cancer". Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects...
What is the current status of trial NCT04844970?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2023-04-01. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT04844970?
The interventions under investigation include: Placebo (DRUG), Anamorelin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04844970?
This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04844970's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI